BioCentury | Sep 9, 2013
Product Development

Checkpoint complementarity

...with advanced cancer. In January, Amplimmune granted Daiichi Sankyo Co. Ltd. an exclusive option to AMP-110...
...a fusion protein containing the extracellular domain of B7-H4 and the Fc-portion of IgG. AMP-110...
BioCentury | Jan 14, 2013
Company News

Amplimmune, Daiichi Sankyo deal

...Amplimmune granted Daiichi an exclusive option to license worldwide rights to develop and commercialize Amplimmune's AMP-110...
...of IgG. This half, Amplimmune and Daiichi plan to start a Phase I trial of AMP-110...
...is eligible for over $50 million in reimbursement for past and planned R&D costs for AMP-110...
BioCentury | Jan 9, 2013
Company News

Amplimmune grants Daiichi option for autoimmune product AMP-110

...Ltd. (Tokyo:4568; Osaka:4568) an exclusive option to license worldwide rights to develop and commercialize Amplimmune's AMP-110...
...of IgG. This half, Amplimmune and Daiichi plan to start a Phase I trial of AMP-110...
...is eligible for over $50 million in reimbursement for past and planned R&D costs for AMP-110...
BioCentury | Aug 9, 2010
Finance

Moving on

...Phase I trial, which CBO Gary Fanger said positions the company to move forward with AMP-110...
...to use this infrastructure to support other programs in the pipeline, like AMP-110," he said. AMP-110...
...MS), lupus and rheumatoid arthritis (RA), as well as in preventing transplant rejection. Fanger believes AMP-110...
BioCentury | Aug 9, 2010
Finance

Amplified Opportunity

...Phase I trial, which CBO Gary Fanger said positions the company to move forward with AMP-110...
...to use this infrastructure to support other programs in the pipeline, like AMP-110," he said. AMP-110...
...MS), lupus and rheumatoid arthritis (RA), as well as in preventing transplant rejection. Fanger believes AMP-110...
BioCentury | Nov 12, 2009
Cover Story

Restoring immunosuppression in RA

...Sol Langermann, VP of R&D, told SciBX that the biotech has developed a fusion protein, AMP-110...
...an optimized version of the agonist described in the paper. The company plans to finalize AMP-110's...
...as anti-TNF-α mAbs that target specific proinflammatory cytokines, AMP-110 has "broad-spectrum activity." "We've shown that AMP-110...
BioCentury | Nov 5, 2009
Distillery Therapeutics

Indication: Autoimmune disease

...soluble B7-H4 as a marker for progression of RA and other rheumatoid diseases. Amplimmune Inc.'s AMP-110...
BioCentury | Aug 31, 2009
Company News

Amplimmune, American National Multiple Sclerosis Society deal

...transfer subsidiary Fast Forward LLC will provide $500,000 in funding for preclinical development of Amplimmune's AMP-110...
...receive warrants to purchase an undisclosed number of shares in Amplimmune at an undisclosed price. AMP-110...
BioCentury | Jun 15, 2009
Emerging Company Profile

Corporate Profile

...Investors: InterWest Partners and Wellcome Trust CEO: Michael Richman Patents: 7 issued covering AMP-224 and AMP-110 BC...
BioCentury | Jun 15, 2009
Emerging Company Profile

Amplimmune: Blocking Immune Evasion

...to note that AMP-224 presents PD-1 with a "native" binding partner. Amplimmune's other compound is AMP-110...
...B7-H4 (V-set domain containing T cell activation inhibitor; VTCN1 ) and the Fc-portion of IgG. AMP-110...
...in preclinical testing for autoimmune diseases, including rheumatoid arthritis. In an animal model of RA, AMP-110...
Items per page:
1 - 10 of 10